By PathGene Biotech · Technically reviewed by Alex Huang
PDRN, GHK-Cu and Ceramide: Personal-Care Formulation Screening Guide
Start with the finished format, not the marketing claim
PDRN, GHK-Cu, and ceramide are used in personal-care formulation research for different reasons, but they do not share one universal process or performance profile. The first screening question is practical: will the ingredient be developed in a water-based serum, emulsion cream, sheet mask essence, ampoule, or another system? The answer determines compatibility, process sequence, preservation, packaging, and stability work.
1. Ingredient-by-ingredient screening
| Ingredient | Formulation questions before scale-up | Common format directions |
|---|---|---|
| PDRN | Confirm molecular-characterization information, solubility or dispersion behavior, preservation compatibility, microbial-control strategy, and the target-market position of the finished product. | Water-based serum, ampoule, mask essence, or emulsion after compatibility testing. |
| GHK-Cu | Evaluate pH window, color change, metal-ion interactions, chelators, preservative compatibility, light exposure, and assay stability over shelf life. | Serum, gel, lotion, cream, or mask essence after stability screening. |
| Ceramide | Confirm the ceramide type, oil-phase or lamellar-system incorporation, heating sequence, dispersion, and emulsion stability. | Cream, lotion, balm, cleanser, or mask-emulsion system. |
2. What published research supports—and what it does not
Published reviews discuss PDRN and related polynucleotides in dermatology research, while the intended use and claims of a finished cosmetic remain market-specific. For GHK-Cu, a recent review identifies topical interest but also notes limited information on permeability, clinical effectiveness, physicochemical properties, and peptide stability. Ceramide literature supports the importance of correct incorporation into final formulations; undissolved ceramides can undermine the intended barrier-focused formulation performance in model systems.
These sources support a research and formulation rationale. They do not establish that every raw-material lot, concentration, or finished product will deliver a clinical effect. Finished-product safety, stability, substantiation, and local claim compliance must be assessed separately.
3. Development checklist
- Set the target dosage form and market before setting a concentration.
- Run appearance, pH, viscosity, odor, color, and compatibility screening with the complete preservative and fragrance system.
- Use accelerated and real-time stability protocols appropriate to the packaging and intended storage.
- Check microbial quality and preservative effectiveness for water-containing systems.
- For peptides and nucleotides, confirm assay stability rather than relying only on appearance.
- Keep raw-material specifications, batch COAs, and final-formulation evidence separate.
PathGene personal-care ingredients
For current material specifications and project documentation, review PDRN, GHK-Cu, and Ceramide. Discuss the finished dosage form, target market, and testing plan with the formulation team before requesting bulk quantities.
References
Kim et al., Pharmaceutics (2025), PDRN and PN in dermatology; Topically applied GHK review (2024); Schild et al., International Journal of Cosmetic Science (2024).
Frequently Asked Questions
Can a raw-material study be used directly as a finished cosmetic claim?+
No. Raw-material evidence does not replace finished-formula safety, stability, substantiation, or local regulatory review.
Which personal-care format should be selected first?+
Choose the format that fits the target market and ingredient compatibility, then confirm pH, preservation, processing, packaging, and stability with the complete formula.
Ready to evaluate our products?
Request a sample or send an inquiry — our R&D team responds within 24 hours.
